Rosetta Genomics Ltd. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported revenues of $870,000 against $404,000 a year ago. Operating income was $1,371,000 against $3,254,000 a year ago. Net comprehensive income from continuing operations was $1,142,000 against $3,260,000 a year ago. Net comprehensive income from discontinued operations was $929,000 against $133,000 a year ago. Net comprehensive income was $2,071,000 against $3,393,000 a year ago. Basic and diluted net income per ordinary share attributable to company shareholders from continuing operations was $0.45 against $1.87 a year ago. Basic and diluted net income per ordinary share attributable to company shareholders from discontinued operations was $0.36 against $0.08 a year ago. Basic and diluted net income was $0.81 against $1.95 a year ago. For the six months, the company reported revenues of $1,608,000 against $788,000 a year ago. Operating income was $4,528,000 against $6,569,000 a year ago. Net comprehensive income from continuing operations was $2,904,000 against $6,605,000 a year ago. Net comprehensive income from discontinued operations was $1,683,000 against $825,000 a year ago. Net comprehensive income was $4,587,000 against $7,430,000 a year ago. Basic and diluted net income per ordinary share attributable to company shareholders from continuing operations was $1.31 against $3.82 a year ago. Basic and diluted net income per ordinary share attributable to company shareholders from discontinued operations was $0.76 against $0.48 a year ago. Basic and diluted net income was $2.07 against $4.30 a year ago. Net cash used in operating activities from continuing operations was $7,051,000 against $4,963,000 a year ago. Purchase of property and equipment was $14,000 against $79,000 a year ago.